Novartis AG

Novartis India's board approved three key agreements with Novartis AG entities, including a royalty-free trademark license and assignment for Tegrital, Voveran, and other brands. The company appointed

Novartis AG sold its entire 70.68% holding (1.74 crore shares) in Novartis India Limited on July 29, 2026. The sale was executed off-market pursuant to a purchase agreement dated February 19, 2026. No

Novartis AG sold its entire 70.68% stake, comprising 1.74 crore equity shares, in Novartis India Limited. The off-market transaction was valued at approximately ₹1,376.89 crore and executed on July 29

Novartis AG completes sale of 70.68% stake in Novartis India to ChrysCapital entities, ceasing to be promoter. ChrysCapital's WaveRise and Fund X acquire control, triggering a mandatory 26% open offer